Recently, China-Saudi Arabia Investment Conference was held in Beijing. As a representative of China's innovative vaccine enterprises, CanSino Bio signed a vaccine cooperation framework agreement with SPIMACO, a Saudi Arabian pharmaceutical manufacturing company, at the Major Investment Collective Signing Ceremony, in which the two parties will cooperate in the commercialization of innovative vaccines, joint R&D and clinical research, as well as localized production.

According to the agreement, the cooperation will focus on promoting the entry of CanSino Bio's quadrivalent conjugate vaccine Manhexin® into Saudi Arabia and other markets in the Middle East and North Africa region. In Saudi Arabia, the quadrivalent conjugate vaccine has been included in the country's childhood immunization program, and there is a strong demand for a quadrivalent conjugate vaccine with longer-lasting immunoprotection effect and higher safety in the local market.

Post-marketing data shows that Mannhexin®, a quadrivalent conjugate vaccine from CanSino Bio, has a very impressive performance in terms of immunogenicity and safety, and can provide stronger and longer-lasting immunoprotection for infants and young children from 3 months of age to 3 years of age (47 months of age), which can satisfy the demand for the prevention of rheumatic encephalopathies in Saudi Arabia.

Ms. Jing Wang, Executive Director and Chief Commercial Officer of CanSino Bio, said, "This agreement is an important milestone for CanSino Bio's entry into the Middle East and North Africa (MENA) market. CanSino Bio is committed to providing innovative, high quality and accessible vaccine products to address unmet medical needs worldwide. Under the concern and strategic guidance of the leaders of the two countries, the company is willing to work with the Saudi side to promote the in-depth connection between the "Belt and Road" initiative and Saudi Arabia's "Vision 2030", and continue to expand the scale of cooperation in the field of biomedicine, so as to contribute to the promotion of China-Saudi Arabia relations into a new era of comprehensive and deepened development.". We will continue to expand the scale of cooperation in the field of biomedicine and contribute to the promotion of Sino-Saudi relations into a new era of comprehensive and deepening development."

Mr. Jerome Cabannes, Chief Executive Officer of SPIMACO, said, "SPIMACO's partnership with CanSino Bio is an important step in building a universal immunization barrier in Saudi Arabia and the surrounding region, and is a key element in the execution of SPIMACO's strategy, which is highly compatible with the company's commitment to promoting the localization of innovative biopharmaceuticals. It is also a key element in the execution of SPIMACO's strategy and fits well with the company's commitment to promoting the localization of innovative biopharmaceuticals. China is a trusted partner of Saudi Arabia in realizing its Vision 2030, and we believe that our cooperation with CanSino Bio will provide new impetus for bilateral economic and trade cooperation, leverage our complementary strengths, and help Saudi Arabia to become a regional biologics manufacturing center for mutual benefit."

The signing of the agreement was completed at the Sino-Saudi Investment Conference held in Beijing, which was attended by Mr. Li Fei, Vice Minister of the Ministry of Commerce of China, Mr. Khalid Al-Falih, Minister of Investment of Saudi Arabia, and other dignitaries of the two countries. The signing ceremony was also attended by Mr. Wang Hongyi, Vice President of CanSino Bio and Dr. Tabassum Khan, Chairman of Stratgurus Group, which contributed significantly to the signing of this agreement as a strategic advisor to SPIMACO.

https://mp.weixin.qq.com/s/RcZCLKOONxjbf81cSC9YdA